As the panelists discuss the skepticism often associated with treatment outcomes of immunotherapy when compared with outcomes of standard treatment options such as chemotherapy, the panelists conclude that tumor response (or reduction) should not be considered an ultimate end point when determining results.
In practice, Daniel J. George, MD, believes that patients’ goals are achieved when they can experience a decent quality of life without experiencing any disease progression. Dr George further explains that some patients that have tumor burden still experience a fantastic quality of life if their treatment side effects are managed correctly.
Jeffrey Weber, MD, PhD, agrees with Dr George and explains that although tumor response is a desirable end point, as recognized by the FDA, it should be perceived as a useful, but not ultimate, result factor.
Research Points to Potential MCIDs in Diabetes Distress Scale–17
November 29th 2023Researchers identified a value of at least 0.25 to be a minimal clinically important difference (MCID) in diabetes distress, and MCID values of 0.38 and 0.39 for emotional and interpersonal distress subscales and physician and regimen distress subscales, respectively.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Insufficient Data, Disparities Plague Lung Cancer Risk Factor Documentation
September 24th 2023On this episode of Managed Care Cast, we speak with the senior author of a study published in the September 2023 issue of The American Journal of Managed Care® on the importance of adequate and effective lung cancer risk factor documentation to determine a patient's eligibility for screening.
Listen
Lawsuits target initiatives aimed at reducing racial disparities; less than 10% of trials for COVID-19 treatments included children in the first 3 years of the pandemic; the World Health Organization requests more information on increased respiratory illnesses in China.
Read More